A total of 158 volunteers each received 21 repeated oral doses of 500 mg of cefuroxime axetil (CAE) during four comparative cross-over trials. Pharmacokinetics were studied in 8 volunteers (CAE versus ampicillin), relative bioavailability and tolerance were studied in 100 volunteers (CAE versus pivmecillinam and CAE versus pivampicillin), and tolerance alone was studied in 50 volunteers (CAE versus Study A. Eight male volunteers each received 21 repeated oral doses of 500 mg of cefuroxime as the acetoxyethyl ester during one of two dosing periods. The study was a crossover comparison with 500 mg of ampicillin in the same dosage regimen during the other period. There was an interval of 3 weeks between dosing periods.
did not change after repeated dosing. Peak serum levels of cefuroxime were significantly higher than those of ampicillin after doses 1 and 21 but the urinary recoveries of both antibiotics were around 35% of the dose. CAE was as well tolerated as ampicillin but there were smaller numbers of episodes of fluid bowel motions on pivmecillinam and pivampicillin than on CAE, which may have been due to the smaller amounts of active antibiotic in the doses of the pivaloyloxymethyl esters.
Cefuroxime is established as a safe, effective antibiotic for the treatment of infections caused by a wide range of bacterial species. Cefuroxime axetil (CAE; cefuroxime as the 1-acetoxyethyl ester) ( Fig. 1 ) is a prodrug of cefuroxime and makes oral rather than parenteral administration of this ,-lactamase-stable cephalosporin possible.
The ester moiety is rapidly cleaved by nonspecific esterase enzymes to yield cefuroxime: cefuroxime acetoxyethyl ester cefuroxime + acetaldehyde + acetic acid This de-esterification probably occurs in the intestinal mucosa and the blood, since no intact ester could be detected in the blood of volunteers after oral doses of CAE when the simultaneous cefuroxime concentration was up to 16 mg/liter (7) . Our Study A. Eight male volunteers each received 21 repeated oral doses of 500 mg of cefuroxime as the acetoxyethyl ester during one of two dosing periods. The study was a crossover comparison with 500 mg of ampicillin in the same dosage regimen during the other period. There was an interval of 3 weeks between dosing periods.
The pharmacokinetics of cefuroxime and ampiciliin were studied after doses 1 and 21 of each antibiotic. On day 1 of each dosing period, the first dose was taken after breakfast, and the second dose was taken 8 h later. Then dosing was three times daily at 0700, 1300, and 1900 after meals for 6 days in each dosing period. On day 8, the last dose was taken just after breakfast.
Blood samples were taken to provide serum for antibiotic assay at the following times after dosing: 0, 30, 60, 90, 120, 150, 180, and 210 min and 4, 5, 6, 7, and 8 h. After allowing the blood to clot for 30 min, the serum was separated by centrifugation at 3,000 rpm for 5 min and stored at -18°C until assay. Four timed urine collections were made from 0 to 2, 2 to 4, 4 to 6, and 6 to 8 h after dosing. The total volume of urine in each collection was mneasured, and a sample was stored until assay to calculate urinary recovery.
From each serum level-time curve, the peak serum level and the time to peak were recorded, and the area under the curve was calculated by the trapezoidal method. Serum and renal clearances were derived from dose and urinary recovery in milligrams, respectively, divided by the area up to 8 h. Clearances were probably overestimated by this method but serum profiles could not be adequately described by a compartmental model, and so areas to infinity could not be estimated. Assays. All assays were performed by high-pressure liquid chromatography on Hypersil octadecylsilane columns. For cefuroxime assays, the mobile phase was 9% acetonitrile with 0.05 M ammonium dihydrogen orthophosphate; the flow rate was 1 ml/min (serum) or 1.6 ml/min (urine). For ampicillin assays, the mobile phase was modified to 6% acetonitrile with 0.05 M ammonium dihydrogen orthophosphate and 0.01% formic acid; the flow rate was 1 ml/min (serum) and 2 ml/min (urine). For mecillinam assays, the conditions were the same as for the cefuroxime assays.
The internal standards used for quantitation were cephaloridine for cefuroxime assays, cephalexin for ampicillin assays, and cefuroxime for mecillinam assays At the end of studies B, C, and D, each volunteer was asked whether he had had any side effects, specifically softening of stools, abdominal pains, extra flatus or flatulence, perianal itching, bitter aftertaste, nausea, and smelly urine. In addition, volunteers were each given a diary in which they recorded all bowel motions from one week before the start through to one week after the end of all dosing. Each motion was given a time on a 24-h clock and an overall rating: 1 = firm, 2 = soft, and 3 = fluid.
Statistical methods. Pharmacokinetic parameters were compared between doses and between drugs by Student's t tests, except for maximum concentration in serum over time, which was compared by Wilcoxon's matched pairs test (T). Chi-squared (x2) tests were used to examine differences between the two drugs in the incidence of fluid motions, gastrointestinal side effects, and codes for abnormal laboratory values. Values of t, T, and x2 were only regarded as significant if they had probabilities of less than 5% (P < 0.05). Fig. 2) .
Studies B and C. Only those volunteers who completed all four urine collections (study B, n = 46; study C, n = 47) have been included in the analysis (Table 2) . In study B, the mean recovery of cefuroxime was significantly greater after dose 21 than after dose 1. Recoveries of cefuroxime were significantly greater than mecillinam in study B after dose 21 only and significantly less than ampicillin in study C after both doses.
Tolerance. All eight volunteers completed both parts of study A without the occurrence of adverse events. One volunteer withdrew from study B because of persistent diarrhea (defined as four or more fluid motions per day) on CAE. Two volunteers withdrew from study C after failing to comply with the protocol. One volunteer in study D had diarrhea and nausea after 14 doses of CAE (during his second dosing period). A cytotoxin which could be neutralized by antibodies raised against clostridial toxin was detected in his stool samples. Symptoms lasted for 2 weeks and were cleared by oral vancomycin; they were probably caused by an antibiotic-induced overgrowth of Clostridium sp. in the large bowel.
In the analysis of the diaries for bowel motions, more fluid stools were noted after CAE than after pivmecillinam (40 versus 22%) and pivampicillin (36 versus 14%) but not after ampicillin (24 versus 28%). Most episodes were short lived and subsided despite continued dosing. As mentioned above, two volunteers stopped dosing whilst on CAE due to persistent symptoms.
Volunteers who did not complete both dosing periods were excluded from the analysis of laboratory safety monitoring (Table 3) . More samples were taken in study D than in studies B and C, and occasional missing samples within each study mean that the total number of tests on each drug was not identical. Most of the abnormal findings were clinically insignificant deviations from normality. Some volunteers had persistently abnormal findings with no overt disease. There were seven volunteers who showed increases in serum transaminase levels (Table 4) , which are recognized side effects of 13-lactam antibiotics (2) .
The only significant differences between drugs in the answers to the questionnaires were in the reporting of bitter aftertaste on CAE in studies B and C (62 to 65% compared with 12 to 15%). However, in these studies the tablets of CAE were not film coated, unlike the tablets of the comparator drugs. A film-coated tablet of CAE has now been formulated which avoids this aftertaste. Softening of the (4, 6) . Induction of nonspecific esterase activity in the gut lumen could reduce the oral bioavailability of esterified prodrugs such as CAE during a treatment course. In study A, the pharmacokinetics of CAE and ampicillin did not change between doses 1 and 21. Also from the data in Table 2 Overall, the urinary recoveries of cefuroxime, ampicillin, and especially mecillinam in studies B, C, and D were lower than reported elsewhere (7, 10, 11) . Some degradation of the antibiotics may have occurred during storage before assay, and this problem would have been more likely with mecillinam.
The incidences of abnormal laboratory findings were around 5% on all drugs, which is the expected figure from a healthy population. The method of calculation of the reference ranges involves the exclusion of 2.5% of the highest and lowest values from the ranges obtained during routine biochemical screens of volunteers.
All four drugs involved in the cross-over comparisons were well tolerated with no cases of hypersensitivity. There was only one systemic disturbance, which was probably due to overgrowth of a toxigenic clostridial strain in the large bowel of a volunteer on CAE. This was the only instance of this side effect in 158 different volunteers who received repeated oral doses of the drug, and the incidence (0.7%) is similar to that reported for other antimicrobial agents (1) .
The greater occurrence of fluid stools with CAE than with the pivaloyloxymethyl esters may have been due to the difference in dose of active antibiotic: 500 mg with CAE, 375 mg with pivampicillin, and 272 mg with pivmecillinam. In contrast, the incidence after CAE and ampicillin (500-mg doses) was almost identical.
It is concluded that CAE is as well tolerated as ampicillin. However, minor bowel disturbances are frequently seen, and these appear related to dose. The relationship between intestinal tolerance and dose should be investigated in the clinic. 
